Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of camrelizumab + apatinib versus paclitaxel or irinotecan as second-line treatment for advanced gastric cancer
CTR20200709Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib, paclitaxel, irinotecan in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Started Sep 2020; status: active.
02
Drugs
camrelizumabRivoceranibpaclitaxelirinotecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20200709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200709.